Lamzede is a medicine used for patients with mild to moderate alpha\-mannosidosis. It is used for treating effects of the disease that do not involve the brain (non\-neurological effects). Alpha\-mannosidosis is an inherited disease with features that include learning disability, difficulty controlling movement, deafness, speaking difficulty, frequent infections, enlarged liver and spleen, bone abnormalities, and muscle pain and weakness. Lamzede contains the active substance velmanase alfa. Alpha\-mannosidosis is rare, and Lamzede was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 26 January 2005\.
Therapeutic Indication
Treatment of non\-neurological manifestations in patients with mild to moderate alpha\-mannosidosis.
Therapeutic Area (MeSH)
ATC Code
A16AB15
ATC Item
N/A
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
EMA Name
Lamzede
Medicine Name
Lamzede
Aliases
N/ANo risk management plan link.
